Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105235 · ClinicalTrials.gov registry record · Phase 2
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00105235 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 27 participants.
The verdict
NCT00105235, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected. This study will determine whether treatment with alemtuzumab and tacrolimus is effective in preventing organ rejection and maintaining the recipient's health after liver transplantation in patients with end-stage liver disease, and whether gradual tapering of tacrolimus treatment is safe for these patients.
Interventions
- DRUG Alemtuzumab
- DRUG Tacrolimus
- DRUG Cyclosporine
- PROCEDURE Liver transplant
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-06 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105235
The ClinicalTrials.gov registry entry for NCT00105235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Alemtuzumab is the first listed.
NCT00105235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105235 about?
NCT00105235 is a clinical study titled "Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients". Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected. This study will determine whether treatment with alemtuzumab and tacrolimus...
What is the current status of trial NCT00105235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2005-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00105235?
The interventions under investigation include: Alemtuzumab (DRUG), Tacrolimus (DRUG), Cyclosporine (DRUG), Liver transplant (PROCEDURE), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00105235?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.